NSE: LAURUSLABS | BSE: 540222

Strong Performer, Getting Expensive

Download real time

822.00 0.50 (0.06%)

New 52W High in past week

675.1K NSE+BSE Volume

NSE 18 Jul, 2025 1:23 PM (IST)

44,373.6

Market Cap

High in industry

1.2

Beta 1Year

Very High Volatility

Board Meeting

The next board meeting for Laurus Labs Ltd. is on 25 Jul 2025 for the purpose of Quarterly Results See details

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

19 Aug 2020

822.00

0.06%

Pharmaceuticals: Expensive e-pharmacy deals; Neutral impact for pharma majors

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Media articles suggest growing consolidation in the e-pharmacy chain, i.e. Reliance-Netmeds and PharmEasy-Medlife.

Laurus Labs Ltd. has an average target of 640.25 from 4 brokers.

Laurus Labs Ltd.

01 Aug 2020

822.00

0.06%

Metamorphosis underway

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

1 August 2020 Laurus Labs (LAURUS) delivered all-time high quarterly PAT at INR1.7b. It is more than average of annual PAT over FY17-20. The company expects this to be sustainable on the back of diversified portfolio, increased customer base, addition of capacity for API/formulation and supported with better operating leverage. After a long wait, the efforts towards product development/building manufacturing base are reflected in the phenomenal financial performance. In fact, 1QFY21 redefines the earnings assessment over near to medium term. Our target PE remains unchanged and target price of INR1,215 at 17x 12M forward earnings factors just the earnings upgrade. Sustainability of growth momentum in FY22 can drive further re-rating. Reiterate Buy. LAURUS 1QFY21 revenues grew at a robust rate of 77% YoY to INR9.7b INR3.5b v/s INR1.1b YoY, Other API (14% of sales) revenue of INR1.3b v/s INR440m YoY, 37% YoY growth in CDMO (10% of sales), and 19% YoY growth in Anti-Viral API (35% of sales).

Laurus Labs Ltd. has gained 44.77% in the last 6 Months

Laurus Labs Ltd.

31 Jul 2020

822.00

0.06%

Laurus Labs (BUY): All-round beat; multiple positives spur big upgrade TP Rs 1,200

Buy: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Laurus Labs reported a record Q1 beat with no major one-offs.

Laurus Labs Ltd. has gained 24.44% in the last 1 Month

Laurus Labs Ltd.

30 Apr 2020

822.00

0.06%

Laurus Labs (BUY): Good beat; firm FY21 outlook target raised to Rs 630

Buy: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Laurus Labs reported a strong operational beat of 8%/20%/41% on sales/EBITDA/ PBT in Q4.

Laurus Labs Ltd. has an average target of 640.25 from 4 brokers.

Laurus Labs Ltd.

24 Mar 2020

822.00

0.06%

First Light | India Strategy: Covid-19, Weekly Eco Wrap

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

India Strategy: Covid-19 - Market bottom elusive stick to select cash-rich stocks. Weekly Eco Wrap: COVID-19 cases jump, so does volatility

Laurus Labs Ltd. has gained 30.88% in the last 3 Months

Laurus Labs Ltd.

31 Jan 2020

822.00

0.06%

Laurus Labs (BUY): Another good beat TP raised to Rs 510

Buy: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Laurus Labs reported a consecutive beat with best-ever Q3 EBITDA, led by strong operating leverage in formulations and higher gross margins.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

28 Nov 2019

822.00

0.06%

Laurus Labs (BUY): NDR takeaways

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

We recently hosted the management of Laurus Labs with investors. Overall, we found management's tone confident yet realistic.

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

01 Nov 2019

822.00

0.06%

Healthy formulation revenue, operating leverage drive earnings

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

ARV-API (-23% YoY) and Hep-C (-47% YoY), however, were weak. Product mix superior: Gross margin expanded 295bp YoY to 49.5%, led by the increased share of FDF sales. EBITDA margin too improved 385bp YoY to 19.3% (our estimate: 17%), led by a better product mix and lower opex (75bp YoY). EBITDA increased 51% YoY to INR1.4b (our estimate: INR1.1b). PAT doubled YoY to INR566m, driven by strong sales growth, superior margins and a lower tax rate. For 1HFY20, revenue/EBITDA/PAT were up 12%/34%/118% YoY to INR12.6b/INR2.3b/INR716m. Key concall highlights: (1) LAURUS has garnered mid-teen market share in...

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

01 Nov 2019

822.00

0.06%

Laurus Labs (BUY): All-round beat formulations turn EBITDA positive; BUY

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Laurus Labs reported its best-ever EBITDA in Q2FY20 with a good topline beat, led by strong operating leverage in the formulation business and gross margin expansion.

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

05 Aug 2019

822.00

0.06%

Laurus Labs (1QFY20): Small hiccup, story is intact. Maintain BUY

Buy: Laurus Labs Ltd.

Target

HDFC Securities

Laurus is sitting on ~40% underutilized gross block (~Rs 0.9bn) spread across formulations, CRAMS and API segments. With a sharp jump witnessed in formulations and higher visibility of CRAMS orders for FY20, we are confident that the operating/ financial leverage story will unfold from FY20. Assuming formulations revenues/ EBITDA at US$ 85/ 25mn in FY21E, earnings are likely to grow 2.5x over FY19-21E. With all four ARV formulation approvals (TLD, TLE 400, TLE 600, TEE) in place by 1HFY21, addressing >US$ 1.2bn opportunity, the estimates could be breached easily. Maintain BUY. We maintain a BUY on Laurus despite poor operational performance in 1QFY20. After adjusting for lack of scale up in ARV APIs and buoyancy in formulation segment, we have cut our FY20/21E numbers by 5-8% to arrive at a TP of Rs 470/sh (18x FY21E EPS).

Laurus Labs Ltd. is trading above all available SMAs

Is Laurus Labs Ltd. worth buying?

1229 Votes:

Buy 79.66%

Sell 10.82%

Hold 9.52%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf